GeoVax Labs shares are trading higher amid continued momentum. Earlier in the week, the company received a BARDA Project NextGen award to conduct a Phase 2b clinical study evaluating its COVID-19 vaccine candidate, GEO-CM04S1.

6/27/24 12:08:57 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GOVX alert in real time by email

Get the next $GOVX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GOVX

Date	Price Target	Rating	Analyst
11/11/2024	$15.00	Buy	Alliance Global Partners
7/16/2024	$20.00	Buy	ROTH MKM

More analyst ratings

$GOVX
Press Releases

Fastest customizable press release news feed in the world

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL). Based on the interim analysis of immune responses from the patients enrolled to date, the DSMB determined that, while the mRNA control arm of the study failed to meet the prede
11/19/24 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
11/12/24 4:00:00 PM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
11/5/24 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care

$GOVX
Leadership Updates

Live Leadership Updates

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
8/8/24 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
1/8/24 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear
12/20/22 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
11/12/24 4:00:00 PM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
11/5/24 9:00:00 AM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin
8/6/24 4:00:00 PM ET
$GOVX
Biotechnology: Pharmaceutical Preparations
Health Care

GeoVax Labs shares are trading higher amid continued momentum. Earlier in the week, the company received a BARDA Project NextGen award to conduct a Phase 2b clinical study evaluating its COVID-19 vaccine candidate, GEO-CM04S1.

Chat with this insight

Recent Analyst Ratings for $GOVX

$GOVX Press Releases

Fastest customizable press release news feed in the world

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

$GOVX Market Insights

Live Market Insights

GeoVax Labs shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and announced an $18 price target.

EF Hutton Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $18

Market-Moving News for July 16th

$GOVX Large Ownership Changes

This live feed shows all institutional transactions in real time.

$GOVX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$GOVX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

SEC Form SC 13G filed by GeoVax Labs Inc.

SEC Form SC 13G/A filed

Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

ROTH MKM initiated coverage on GeoVax Labs with a new price target

President, CEO Dodd David A bought $15,600 worth of shares (8,000 units at $1.95), increasing direct ownership by 43% to 26,661 units (SEC Form 4)

Dodd David A bought $19,781 worth of shares (8,729 units at $2.27), increasing direct ownership by 88% to 18,661 units (SEC Form 4)

Reynolds Mark bought $5,540 worth of shares (2,000 units at $2.77), increasing direct ownership by 38% to 7,213 units (SEC Form 4)

$GOVX Leadership Updates

Live Leadership Updates

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

$GOVX SEC Filings

$GOVX Financials

Live finance-specific insights

$GOVX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

GeoVax Labs Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

GeoVax Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form 424B3 filed by GeoVax Labs Inc.

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

SEC Form 4 filed by President, CEO Dodd David A

SEC Form 4 filed by Chief Medical Officer Mckee Kelly T. Jr.

SEC Form 4 filed by Chief Scientific Officer Newman Mark J

Recent Analyst Ratings for
$GOVX

$GOVX
Press Releases

$GOVX
Market Insights

$GOVX
Large Ownership Changes

$GOVX
Analyst Ratings

$GOVX
Insider Purchases

$GOVX
Leadership Updates

$GOVX
SEC Filings

$GOVX
Financials

$GOVX
Insider Trading